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ABSTRACT 
Gastrointestinal (GI) cancers are among the most deadly malignancies.  Whereas 
serial incremental survival benefits have been made with cytotoxic chemotherapy 
with metastatic disease, a plateau of achievement has been reached.  Applying modern 
integrative genomic technology, distinct molecular subgroups have been identified in 
GI cancers.  This not only highlighted the heterogeneity in tumours of each primary 
anatomical site, it also identified novel therapeutic targets in distinct molecular 
subgroups and might improve the yield of clinical success.  Molecular characteristics 
of tumours and their interaction with tumour microenvironment would further impact 
on development of combination therapy, including immunotherapy.  Currently 
immune checkpoint blockade attracts the most intense research and the successful 
integration of these novel agents in GI cancers in the treatment paradigm requires an 
in-depth understanding of the diverse immune environment of these cancers.   
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INTRODUCTION 
Cancers of gastrointestinal (GI) tract are among the most deadly malignancies with a 
high mortality to incidence ratio.  Oesophago-gastric (OG), pancreatic, liver and 
colorectal (CRC) cancers account for more than 2,894,000 deaths per annum (1).  
Whereas serial incremental survival benefits have been made with cytotoxic 
chemotherapy with metastatic OG and colorectal cancers, a plateau of achievement 
has been reached.  Applying modern integrative genomic technology, distinct 
molecular subgroups have been identified in GI cancers.  This not only highlighted 
the heterogeneity in tumours of each primary anatomical site, it also identified novel 
therapeutic targets in distinct molecular subgroups and might improve the yield of 
clinical success.  Molecular characteristics of tumours and their interaction with 
tumour microenvironment would further impact on development of combination 
therapy, including immunotherapy. 
 
Currently immune checkpoint blockade especially targeting Programmed Death -1 
(PD-1) and Programmed Death Ligand (PD-L)1 attracts the most intense research.  
PD-1 is a cell surface co-inhibitory receptor expressing in T cells, B cells, monocytes 
and natural killer (NK) cells.  It has two known ligands – PD-L1 and PD-L2.  PD-L1 
is up-regulated by tumour cells and by cells in the tumour microenvironment.  PD-1 
interaction with its ligands inhibits T-cell receptor signalling and down-regulates T-
cells responses.  Inhibition of PD-L1 could restore T cell activity against tumour cells, 
thereby preventing cancer metastasis and reducing tumour volume (2).  This review 
focuses on the current and future approach of immunotherapy and its interface with 
the recent genomic data from GI cancers.  
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OESOPHAGO-GASTRIC CANCER 
There have been several large scale research efforts to ascertain molecular 
subgrouping for gastric cancer.  Notably the Cancer Genome Atlas (TCGA) identified 
four groups – Epstein Barr Virus (EBV) infected (9%), Microsatellite Instability (MSI 
22%). Genomically Stability (GS 20%) and Chromosomal Instability (CIN 50%) (3). 
The Asian Cancer Research Group (ACRG) also described 4 subgroups – MSI 
(22.7%), Microsatellite Stable (MSS)/ epithelial-to-mesenchymal transition (EMT 
15.3%), MSS/TP53 positive (26.3%) and MSS/TP53 negative (35.7%) (4).  However 
of note the four subgroups described by the TCGA did not carry any prognostic 
effect, although this might be partly due to the tumour samples deriving from operable 
OG cancers with limited follow-up (3).  Furthermore, several molecular aberrations 
overlapped between different subgroups and thus these might not be completely 
distinct subgroups.  For example PIK3CA mutations were frequently observed in the 
EBV subgroup, but were also found, albeit less frequently, in the MSI, GS and CIN 
subgroups.  In contrast the four subgroups identified by the ACRG did have 
statistically significant survival differences (4).  This prognostic difference between 
TCGA and ACRG was not necessarily related to the limited follow-up of the TCGA.  
In addition, the semi-supervised analysis used by the ACRG with the incorporation of 
clinical characteristics might have contributed to this difference (3, 4).  Within the 
EBV-infected and MSI gastric cancer described in the TCGA, there were significantly 
higher expression of PD-L1 in both the tumour cells and immune cells compared to 
other subgroups (5, 6).  Furthermore interferon-γ gene set enrichment was also more 
frequently seen in the EBV-infected and MSI subgroups, although there was no 
association between interferon-γ signature and total number of mutations (5).  These 
subgroups might be particularly sensitive to PD-L1 blockade and of enhanced 
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relevance especially MSI gastric tumours might have a negative prognostic impact 
when treated with cytotoxic chemotherapy (7). 
 
The initial enthusiasm in targeting PD-L1 in gastric adenocarcinoma came from the 
results of pembrolizumab in PD-L1 positive gastric cancer in the KEYNOTE-012 
study (8).  In this study, patients from both Asian and non-Asian countries were 
enrolled.  Forty per cent of screened population were found to be PD-L1 positive in a 
relatively heavily pre-treated patient population.  An objective response rate (ORR) of 
22% on central review and durable responses were seen with median duration of 
responses of 40 weeks.  Six-month progression free survival (PFS) rate was 26% and 
impressively the median overall survival (OS) was 11.4 months with 12-month OS 
rate of 42%.  Based on these, several randomised controlled trials (RCTs) have 
been/are being performed.  Table 1 shows selected on-going randomised studies 
evaluating PD-(L)1 antibodies in GI cancers.  In the second line KETNOTE-061 
RCT, patients were not initially pre-selected for tumour PD-L1 expression, but PD-L1 
positive patients were enriched at a latter part of the study.  In the first line 
KEYNOTE-062 study, only patients with PD-L1 positive OG cancer are being 
recruited as this 3-arm RCT has a pembrolizumab alone treatment arm without any 
cytotoxic chemotherapy and data from KEYNOTE-012 were on PD-L1 positive 
gastric cancer alone.   
 
Nivolumab has also been evaluated in a number of studies in gastric cancer.  In the 
CHECKMATE 032 study, both nivolumab monotherapy and the combination of 
nivolumab plus ipilimumab were tested in gastric cancer patients.  The combined PD-
L1 and CTLA-4 targeting were first found to be valuable in malignant melanoma (9), 
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but more recently in other tumours such as small cell lung cancer (10).  
CHECKMATE 032 gastric cohort recruited 160 gastric cancer patients who were 
allocated non-randomly to nivolumab (3mg/kg) monotherapy (n=59) and two dose 
schedules of nivolumab plus ipilimumab – nivolumab 1mg/kg and ipilimumab 
3mg/kg (nivo 1 ipi 3; n=49) or nivolumab 3mg/kg + ipilimumab 1mg/kg (nivo 3 ipi 1; 
n=52) (11).  Similar to KEYNOTE-012, a heavily pre-treated patient population was 
recruited with 79% of patients had had ≥2 prior therapy.  However unlike KETNOTE-
012, patients were enrolled irrespective of PD-L1 expression status and all patients 
were of Western population.  The ORR was 14% (nivo alone), 26% (nivo 1, ipi 3) and 
10% (nivo 3, ipi1).  The median duration of response was 7.1 months, 5.6 months and 
not reached respectively.  Six-month PFS was 18%, 24% and 9% and 12 month OS 
was 36%, 34% and not available respectively.  There was some correlation between 
ORR and PD-L1 expression for nivo alone, but less so with the combination of nivo 
and ipi similar to the observation in malignant melanoma (9, 11).   
 
Most recently a phase III placebo-controlled RCT was reported for nivolumab in third 
or subsequent line therapy.  The ONO12 (ATTRACTION-2) study only recruited 
patients in Korea, Japan and China and thus consisted entirely of Asian population 
(12).  In this large study, 493 patients were randomised in a 2:1 fashion to nivolumab 
or placebo. Nivolumab resulted in statistically superior OS (hazard ratio [HR]: 0.63; 
95% confidence interval [CI]: 0.50-0.78; p<0.0001), PFS (HR: 0.60; 95%CI: 0.49-
0.75; p<0.0001) and ORR.  Twelve month OS rates were 26.6% and 10.9% and ORR 
was 11.2% vs 0% for nivolumab and placebo respectively.  Whereas the ONO-12 and 
CHECKMATE 032 showed similar efficacy for nivo alone in both Asian and Western 
populations, it has been previously shown that the Asian and non-Asian gastric cancer 
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might exhibit distinct gene signatures related to inflammation and immunity (13).  In 
particular, immune T cell expression signatures were enriched in non-Asian gastric 
cancers including both CD28 and CTLA-4 signalling with supportive 
immunohistochemistry data showing T-cell markers (CD3, CD45R0 and CD8) 
significantly enriched in Caucasian compared with Asian GC.  The exception was the 
immunosuppressive T-regulatory cell marker FOXP3 which was significantly 
enriched in the Asian population.  These immune-related differences were however 
unrelated to EBV infection and MMR status.  
 
Avelumab, an anti-PD-L1 antibody, had been evaluated in a phase IB expanded 
cohort JAVELIN study in two different settings – maintenance post first line therapy 
and second line treatment (14).  In the second line setting, ORR was similar to 
nivolumab and pembrolizumab.  Maintenance setting has so far not been explored by 
other PD-1 antibodies and forms the current registration strategy for avelumab in 
gastric cancer (Table 1).   
 
When one interrogated the integrated molecular description of gastric cancer in the 
TCGA, both JAK2/PD-L1/2 and VEGF A were altered in the CIN subgroup.  
Targeting angiogenesis is now an established treatment options in gastric cancer (15, 
16).  Vascular Endothelial Growth Factor Receptor (VEGFR) 2 pathway activation by 
VEGF-A might suppress antitumour T cell activation by i) blocking the maturation of 
dendritic cells disrupting tumour antigen presentation; ii) inducing the expression of 
PD-L1 on dendritic cells; iii) enhancing regulatory T-cell which could inactivate 
antitumour immune cells (17, 18). In addition, preclinical evidence has shown low 
vascular normalizing doses of anti-angiogenics such as DC101 (murine parent 
9 
antibody to ramucirumab targeting VEGFR2) reprogrammed the tumour 
microenvironment from immunosuppressive to immunosupportive and potentiated 
immunotherapy (19).  In contrast high dose DC101 might prune tumour blood vessels 
and promote immunosuppressive tumour microenvironment.  Furthermore, there were 
further data suggesting synergistic inhibitory effect of DC101 with anti-PD1 antibody 
in a colon adenocarcinoma murine model (20).   
 
With this background, a phase 1 study was initiated combining pembrolizumab and 
ramucirumab in PD-L1 unselected multi-tumour patient cohorts.  Second/third line 
gastric cancer cohorts were examined in two different dose schedule (low dose or 
high dose ramucirumab plus fixed dose pembrolizumab) (21).  A further first line 
chemonaïve cohort was also being explored.  The safety profile of ramucirumab 
combined with pembrolizumab was favourable allowing administration of each drug 
at full dose.  Some anti-tumour activity was observed in previously treated gastric 
adenocarcinoma but data were immature for survival endpoints (21).  No results are 
currently available for the chemonaïve cohort.  Similar to targeting angiogenesis, 
another combination strategy of targeting the tumour microenvironment with 
immune-oncology (IO) compounds would be against matrix metalloproteinase 
(MMP)-9 and PD-L1.  A randomised phase 2 study of nivolumab with or without 
andecaliximab (GS-5745) is on-going (Table 1). 
 
There are a number of adaptive designed phase II studies either recruiting or being 
planned to combine different IO agents in gastric cancer.  For example FRACTION 
(A phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-
Oncology study in patients with advanced gastric cancer) is currently randomising 
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nivo + ipi with nivo + BMS-986016 (anti-LAG3 antibody), with further combination 
IO compounds to be added in future (Table 1).   
 
TCGA also recently reported the genomic characterisation of oesophageal carcinoma 
(22).  As one would expect, squamous cell carcinoma (SCC) and adenocarcinoma 
were molecularly distinct.  Oesophageal adenocarcinoma strongly resembled the CIN 
variant of gastric adenocarcinoma, although DNA hypermethylation occurred 
disproportionately in oesophageal adenocarcinoma.  No oesophageal 
adenocarcinomas were positive for MSI or EBV.  In contrast SCC revealed frequent 
alterations in cell cycle regulators with inactivation of CDKN2A and amplification of 
CCND1.  Furthermore EGFR amplification or mutation was seen in 19% and 
alterations of PIK3CA, PTEN or PIK3R1 in 24% of tumours.  TCGA divided 
oesophageal SCC into three molecular subtypes: ESCC1 characterised by alteration in 
NRF2 pathway and resembled more close to lung and Head & Neck SCC; ESCC2 
showed higher rate of mutation of NOTCH1 or ZNF750 and greater leucocyte 
infiltration; ESCC3 sustained alterations predicted to active the PI3K pathway.  With 
the success of nivolumab in SCC Head and Neck (23) and Lung (24), ESCC1 might 
be a subgroup more susceptible to PD-1 targeting.   
 
The first study of targeting PD-1 in SCC oesophagus was recently published (25).  
This was conducted entirely in Japan with 65 patients enrolled and it was unselected 
for tumour PD-L1 positivity.  An ORR of 17% on central review and median OS of 
10.8 months were observed. Interestingly immune-related ORR was 25%.  
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COLORECTAL CANCER 
 
Similar to OG cancer, there has been several large scale efforts to define molecular 
subgroups in CRC.  Indeed a consensus molecular subgroup (CMS) has been 
proposed (26).  CMS1 (MSI Immune), CMS 2 (Canonical), CMS 3 (Metabolic) and 
CMS 4 (Mesenchymal) had different molecular characterisation.  Of particular 
interest CMS 1 had MSI and thus hypermutation with immune infiltrate activation.  
This subgroup had worse survival after relapse.  For CMS 4 mesenchymal, there was 
stromal infiltration, TGF-β activation and angiogenesis.  This subgroup had worse 
relapse-free and overall survival.   
 
The immune landscape of these CMS had also been explored (27).  CMS 1 and 4 had 
high expression of lymphoid as well as myeloid cell-specific genes, thus exhibiting a 
strong immune and inflammatory contexture.  However, the poor prognostic CMS 4 
differed from CMS1 with higher expression of endothelial cell and fibroblast genes.  
In addition, functional relevant immune genes were also up-regulated in CMS 1 and 
CMS 4.  CMS1 exhibited a high expression of genes coding for T-cell-attracting 
chemokines or involved in formation of tumour adjacent tertiary lymphoid structures, 
all associated with good prognosis in CRC.  In contrast CM4 exhibited high 
expression of myeloid chemokine, angiogenic factors and immune-suppressive 
molecules (27).  CMS2 and CMS3 might potentially be “immune deserts” consisting 
up to 50% of CRC cases whereas CMS1 and CMS 4 resembled more of “immune 
paradise” although CMS 4 also had inflammatory and angiogenic components (Figure 
1). 
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In the early development of anti-PD (L)1 antibodies, only marginal if any benefit was 
seen in metastatic CRC (mCRC).  Much more encouraging efficacy was seen in a 
small subgroup of patients with mismatch repair (MMR) deficient mCRC.  This 
subgroup only constituted ∼4-5% of all patients with mCRC.  ORR of 62% was 
reported in 13 patients with MMR-deficient CRC using pembrolizumab whereas no 
response was observed in 25 patients with MMR-proficient CRC (28).  In this study, 
85% of patients with MMR deficiency were of Lynch Syndrome families.  
Preliminary PFS and OS were all superior in the MMR deficient compared to MMR 
proficient patients (p=0.001 and p=0.03 respectively) when treated with 
pembrolizumab (28).  In an updated analysis, a total of 53 patients (28 MMR deficient 
and 25 MMR proficient) were treated.  ORR was 50% for MMR deficient CRC and 
0% for MMR proficient CRC, respectively. For MMR deficient CRC, the PFS rates 
was 61% at 24 months and the OS rate was 66% at 24 months (29).  The number of 
somatic mutations was significantly higher in the MMR-deficient tumours compared 
to MMR proficient and this correlated with objective response (28).  Mutation rate 
and neoantigen load might contribute to sensitivity to anti-PD-1 antibodies (30, 31), 
although this might not be an universal phenomenon in GI cancers.   
 
A further study was recently reported evaluating nivolumab ± ipilimumab for MMR 
deficient mCRC (32, 33).  Larger number of patients were recruited in this study 
(n=74) and ORR of 20% was observed for nivolumab monotherapy.  Twelve-month 
PFS and OS rates were 48% and 74% respectively.  The proportion of Lynch family 
in this study was 31%.  Responses were seen regardless of tumour PD-L1 expression, 
abundance of PD-L1 expressing tumour-associated immune cells, B raf mutation or 
Lynch syndrome.  In addition there was improvement of QoL observed after 
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nivolumab approaching the population norm (32).  The combination of nivo + ipi 
resulted in ORR of 33.3%.  Six month PFS and OS rates were 66.6% and 85% 
respectively with the combination (33).  Similar to pembrolizumab study, only one 
response was seen out of 20 patients with MMR proficient tumours.   
 
In mCRC, the challenge remains how to convert the MSS tumours and “immune 
desert” like CMS2 and CMS3 to be more responsive to immunotherapy.  There was 
preclinical evidence to suggest MEK inhibition alone could result in intratumoral 
CD8+ effector T-cell accumulation and MHC 1 up-regulation.  This synergised with 
anti-PD1 agent to promote durable tumour regression (34).  With this rationale, a 
phase 1 study of cobimetinib (MEK inhibitor) with atezolizumab (PD-L1 antibody) 
was conducted with an expanded cohort in mCRC (n=23).  ORR of 17% was 
observed in all mCRC patients and 20% in KRAS mutant CRC cohort (n=20) (35).  
This contrasted with almost 0% response seen in MSS patients treated with PD-1 
antibodies.  Based on this, a phase III trial (COTEZO) has completed recruitment for 
mCRC patients at third or subsequent line treatment randomising to regorafenib 
(control), atezolizumab or cobimetinib plus atezolizumab (Table 1).   
 
Aside from PD1 blockade, there are other immunotherapy strategies being actively 
pursued in mCRC.  Bispecific T cell engager (BiTE) are molecules that recruit and 
engage T cells through simultaneous binding to the CD3ε subunit of the T cell 
receptor complex and a tumour surface antigen, which results in T cell cross linking 
(36).  One FDA-approved BiTE is blintumumab, a CD19/CD3 BiTE used for acute 
lymphoblastic leukaemia.  For mCRC and GI cancers generally, CEA would be a 
suitable tumour surface antigen.  MEDI-565/AMG 211 was a CEA and CD3 
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bispecific single-chain antibody and it was found in preclinical model that it mediated 
T cell directed killing of CEA positive cells and this activity was independent of the 
mutational status of cancer cell lines such as KRAS/BRAF/PI3KCA mutation, loss-of-
function mutation in TP 53 or PTEN loss (37).  This preclinical activity was also seen 
in patients’ CEA+ CRC specimens (38).  A phase 1 study was initiated for MEDI-565 
for GI adenocarcinoma.  Thirty-nine patients were recruited with the majority having 
mCRC.  The dose limiting toxicities seen were hypoxia and cytokine release 
syndrome (39).  Unfortunately no objective response was seen and it was unclear how 
many patients had CEA-positive tumours.   
 
Another new CEA-T cell bispecific antibody (TCB) has been developed (RG7802) 
and this CEA TCB had a bivalent binding to CEA and monovalent binding to CD3ε 
subunit of T cell receptor (36, 40).  Preclinically CEA TCB was found to mediate 
efficient T cell dependent tumour cell lysis by inducing stable crosslinking of multiple 
T cells to individual tumour cells.  It demonstrated efficacy in non-inflamed and 
poorly T-cell infiltrated tumours.  It increased T cell infiltration in tumours converting 
non-inflamed, PD-L1 negative tumours to highly inflamed PD-L1 positive tumours 
leading to a more inflamed tumour microenvironment (36, 40) which also paved the 
way to future combination of CEA TCB and PD-(L) 1 antibodies.  Cergutuzumab 
amunaleukin (RO6895882) is another strategy of immunocytokine which consists of a 
variant of interleukin 2 that targets CEA.  A combination study of RO6895882 and 
atezolizumab is being performed in various CEA-expressing solid tumours including 
colorectal and pancreatic cancers.   
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Another approach that has been evaluated in mCRC was activating innate immune 
response with toll like receptor (TLR) agonists (41).  TLRs are key components of the 
innate immune system and are essential for the recognition of pathogen-associated 
molecular pattern (PAMP) and/or damage-associated molecular pattern (DAMP) 
molecules.  The release of DAMP resulted from non-infectious inflammatory 
response.  Whereas host inflammatory cells would attempt to destroy malignant cells, 
if this acute inflammatory response was insufficient to fully destroy the developing 
tumour, a dysregulation of the immune system could occur resulting in a chronic 
inflammatory response typified by production of large numbers of certain innate 
immune cells ultimately promoting the growth and progression of cancer (42, 43).  
Currently 10 human TLRs have been identified.  TLR-9 is located in the plasmacytoid 
dendritic cells, but also expressed on majority of innate and adaptive (CD4+, CD8+, 
NK T and γδ T) effector cells and in B cells.  During tumour cell death, mtDNA and 
mitochondrial formyl peptides are released, which may act as DAMP and potentially 
result in the dysregulation of TLR-9. 
 
The first generation TLR-9 agonist developed was a CpG oligodeoxynucleotides 
(CpG-ODN) called PF3512676.  Unfortunately when added to standard chemotherapy 
in non-small cell lung cancer, no survival benefit was seen (44, 45).  The second 
generation TLR-9 agonist also halted development due to toxicity and lack of 
efficacy.  The next generation TLR-9 agonist, lefitolimod (MGN 1703) underwent 
further structural changes which might improve efficacy and safety.  Lefitolimod has 
been found to be much more potent than CpG-ODN with evidence of immune 
activation in heavily pre-treated patients with solid tumours and mCRC in particular.  
Both innate and adaptive immune responses were seen in vivo (41).  Lefitolimod was 
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tested in a small randomised placebo controlled trial as maintenance therapy.  Patients 
who had completed first line therapy with oxaliplatin or irinotecan/ fluoropyrimidine 
± bevzcizumab were randomly allocated to lefitolimod or placebo (46).  There was a 
trend towards better PFS with lefitolimod from randomisation and statistically 
significant better PFS from start of induction therapy.  In addition, the greatest benefit 
of lefitolimod appeared to be in patients with relatively low tumour burden.  
Therefore IMPALA, the phase III RCT of lefitolimod, is recruiting 540 mCRC 
patients with at least partial responses to first line therapy as maintenance therapy.  
The addition of pembrolizumab to TLR-4 agonist is also being evaluated in other 
tumours such as follicular lymphoma.  A phase 1b/2 study is designed to evaluate 
intratumoural G100 (TLR-4 agonist) plus local radiation and pembrolizumab versus 
G100 plus local radiation alone in patients with follicular lymphoma (NCT: 
02501473). 
 
As prognostication, the Immunoscore has gained much recent attention.  Taking into 
the account of the proportion of cytotoxic and memory T cells as well as their location 
– tumour centre or invasive margin (47, 48), patients with high Immunoscore had a 
much more favourable time to recurrence in a recent multinational validation project 
(49).  The challenge is whether Immunoscore could be incorporated into predictive 
biomarker for checkpoint inhibitors in mCRC.   
 
PANCREATIC CANCER 
 
Integrated analysis of genomic, epigenomic and transcriptomic characteristics in 
pancreatic ductal adenocarcinoma (PDAC) had also identified 4 molecular subtypes: 
squamous; pancreatic progenitor; aberrantly differentiated endocrine exocrine 
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(ADEX) and immunogenic (50).  Yet checkpoint inhibition in PDAC had been 
disappointing thus far.  The immune environment of PDAC might be particularly 
hostile.  This was characterised by i) sparse intratumoural cytotoxic CD8+ effector T 
cells; ii) RAS oncogene driving inflammatory programme; iii) CD3+ T cell 
sequestering preferentially at tumour margin and iv) excessive immunosuppressive 
leucocytes in tumour microenvironement (51).  In a recent pooled analysis of TCGA 
and ICGC (International Cancer Genome Consortium) PDAC data (52), it was found 
that T cells were present but inactive.  Robust tumour infiltrating lymphocytes were 
present but T-cell activation signature was absent.  Contrary to other tumours, high 
mutation load in PDAC was inversely related with T-cell activity (52). 
 
PD-L1 positive PDAC had less favourable prognosis although expression was sparse 
(53).  In a phase II study of ipilimumab in metastatic pancreatic cancer, no objective 
response was observed out of 23 patients although 1 patient had immune related 
response (54).  In another study of ipilimumab with or without GVAX, a vaccine 
based on allogeneic pancreatic tumour cells genetically modified to produce GM-
CSF, again no responses was seen although decrease in CA19-9 marker level was 
observed when GVAX was added (55).  Furthermore in a phase 1 study of PD-L1 
antibody, there were no responses seen out of 14 patients with PDAC (56).  In MMR 
deficient pancreatic cancer, objective responses have been seen with pembrolizumab 
but patient number was extremely limited (57).   
 
The largest study evaluating immunotherapy approach in advanced PDAC was the 
TELOVAC study (58).  GV1001, a human telomerase reverse transcriptase catalytic 
subunit (hTERT) class II peptide vaccine was given either sequentially after 
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chemotherapy or concomitantly with chemotherapy.  Gemcitabine plus capecitabine 
was given both as control arm and also as chemotherapy with GV1001 in the 
experimental arms.  TELOVAC was probably the largest RCT ever conducted in 
advanced PDAC with 1,002 patients randomised to these three arms.  Unfortunately 
no survival benefit was seen with this immunotherapeutic approach (58). 
 
The “immune desert” of pancreatic cancer represented a major therapeutic challenge.  
Interestingly preclinically, similar to mCRC, there was evidence that combining MEK 
and PD-1 inhibition exhibiting greater inhibitory effect on tumour growth compared 
to PD1 inhibition or MEK inhibition alone (59).  Myeloid cells protected pancreatic 
tumour cell viability by blocking CD8+ T cell-mediated anti-tumour response.  This 
was achieved by activating PD-1/PD-L1 checkpoint through EGFR/MAPK signalling.  
Depletion of myeloid cells in the microenvironment arrested tumour growth or 
induced tumour regression.  Increased level of immunosuppressive leucocytes and 
desmoplastic stroma forming barrier to T-cell infiltration represented critical obstacles 
to immunotherapy in PDAC.  Focal adhesion kinase (FAK) might be important for 
regulating fibrotic PDAC tumour microenvironment.  FAK inhibition induced tumour 
stabilisation, decreased fibrosis without accelerating tumour progression and 
decreased immunosuppressive cell population in tumours (60).  FAK inhibition 
(FAKi) improved survival the most with FAKi + Gemcitabine + antiPD1/antiCTLA 4 
therapy in mice bearing transplantable KRAS mutated pancreatic tumours (60). 
 
BILARY TRACT CARCINOMA  
Primary biliary tract cancers (BTC) consists of cholangiocarcinoma – intrahepatic 
(ICC) and extrahepatic (ECC) as well as gallbladder cancer.  They arise from 
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malignant transformation of biliary epithelium, typically occurring in the setting of 
chronic inflammation (61).  Expression of PD-1 and PD-L1 is up-regulated in ICC 
tumour tissues (62).  Increased expression of PD-L1 was associated with poor 
differentiation and stage of ICC whereas increased CD8+ T cells in tumours was 
associated with better tumour differentiation.   
 
In a series of resected ICC, the majority of tumours expressed PD-L1 on tumour cells 
located either within the tumour front or on tissue-associated macrophages (TAMS) 
(63).  PD-L1 expression was found to be associated with nodal metastasis and larger 
number of lesions.  PD-L1 expression within the tumour front was associated with 
worse survival, suggesting the PD-1 pathway might be suppressing the host immune 
response in ICC (63).  In another study, all resected ICC expressed PD-1 which was 
present on tumour-infiltrating lymphocytes but was not detected on ICC cells (64) .  
Whereas immune infiltrate was present in all tumour analysed, the proportion of 
CD8+ T cells was significantly higher in the fibrous septa compared to tumour 
lobules (64).  ICC tumours with down-regulation of HLA Class I antigen expression 
presented with more advanced stage.  Therefore this microenvironment might 
potentially attractive for an PD-(L) 1 antibody therapy.   
 
There is paucity of clinical data in the use of anti-PD-(L)1 antibody in advanced BTC.  
Pembrolizumab was tested in a multi-cohort phase IB KEYNOTE – 028 (65).  Only 
patients with PD-L1 positive tumours were recruited.  Of the screened advanced BTC 
population, 42% were  PD-L1 positive.  Twenty-four patients were recruited and ORR 
of 17% was observed (65).  In the aforementioned phase 1 study evaluating 
pembrolizumab plus ramucirumab in gastric cancer patients, there was a separate 
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cohort of advanced BTC patients which have completed recruitment, but no results 
are available yet.   
 
Hepatocellular carcinoma has distinct immune environment which might represent 
potential “immune paradise” for checkpoint inhibition.  However a separate review 
article will focus on this particular subject.   
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CONCLUSIONS 
 
There are still much data with immunotherapy in GI cancers not discussed in this 
review – active immunotherapy with dendritic cell vaccine, viral vector vaccine; 
passive immunotherapy like chimeric antigen receptor (CAR) T cell therapy and other 
checkpoint modulators such as LAG3, OXO40, KIR, TIM-3.  Combining 
radiotherapy (RT) with PD-(L) 1 antibodies to enhance anti-tumour T cell response 
and augment abscopal effect is also being actively pursued in GI cancers.  This 
abscopal effect where a non-irradiated site regresses after RT to the primary tumour 
might stem from an immune-related mechanism and synergistic effect of RT and PD-
(L)1 antibodies hyave been observed in preclinical models.  The immune landscape of 
GI cancer is wide-ranging with immune paradise and immune desert.  Integrating 
information collected from genomic analysis and immune microenvironment would 
hopefully turn these into immune oasis and provide greater opportunities in 
immunotherapy for the greater benefits of our patients.   
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Table 1 Selected on-going randomised studies evaluating PD-(L)1 antibodies in gastrointestinal cancers 
Trial protocol /  
NCT ID 
Study setting Phase Treatment Arms Planned 
recruitment 
number of 
patients 
 
Primary outcome 
Gastric and OGJ cancers 
 
    
ONO-4538-38 
NCT 03006705 
Adjuvant III 1) CAPOX or S-1 + placebo 
2) CAPOX or S1 + nivolumab 
 
700 Relapse free survival 
FRACTION 
NCT 02935634 
Advanced/ metastatic 
≥2nd line 
II 
adaptive 
1) Nivolumab + ipilimumab 
2) Nivolumab + BMS-986016 (anti-
LAG 3 antibody) 
3) Nivolumab + other IO compounds 
 
910 ORR 
DOR 
PFS rate 
ONO-4538-37 
NCT 02746796 
 
Advanced/ metastatic 
1st line 
II 1) SOX or CAPOX 
2) SOX or CAPOX + nivolumab 
268 ORR 
CHECKMATE 649 
NCT 02872116 
Advanced/ metastatic 
1st line 
III 1) CAPOX or FOLFOX 
2) CAPOX + nivolumab 
3) Nivolumab + ipilimumab 
 
1,266 OS 
GS-US-296-2013 
NCT 02864381 
 
Advanced/ metastatic 
≥2nd line 
II 1) Nivolumab 
2) Nivolumab + GS-5745 (anti-MMP 9 
antibody) 
120 ORR 
34 
Trial protocol /  
NCT ID 
Study setting Phase Treatment Arms Planned 
recruitment 
number of 
patients 
 
Primary outcome 
 
KEYNOTE 061 
NCT 02370498 
 
Advanced/ metastatic 
2nd line 
III 1) Paclitaxel  
2) Pembrolizumab 
720 OS/ PFS 
KEYNOTE 062 
NCT 02494583 
 
Advanced/ metastatic 
1st line 
III 1) Cisplatin + fluoropyrimidine + 
Placebo 
2) Cisplatin + fluoropyrimidine + 
pembrolizumab 
3) Pembrolizumab 
 
750 PFS/ OS 
KEYNOTE 063 
NCT 03019588 
 
Advanced/ metastatic 
2nd line 
III 1) Paclitaxel 
2) Pembrolizumab 
360 OS/ PFS 
JAVELIN 
GASTRIC 300 
NCT 02625623 
 
Advanced/ metastatic 
3rd line 
III 1) Best supportive care 
2) Avelumab 
330 OS 
JAVELIN 
GASTRIC 100 
NCT 02625610 
 
Advanced/ metastatic 
1st line maintenance 
III 1) Continuation of 1st line chemotherapy 
2) Avelumab 
 
666 OS 
PLATFORM 
NCT 02678182 
 
Advanced/ metastatic 
1st line maintenance 
II 1) Observation 
2) Capecitabine 
3) Durvalumab 
616 PFS 
35 
Trial protocol /  
NCT ID 
Study setting Phase Treatment Arms Planned 
recruitment 
number of 
patients 
 
Primary outcome 
 
Oesophageal cancer 
 
     
CHECKMATE 473 
ONO-4538-24 
NCT 02569242 
 
Advanced/ metastatic 
≥2nd line 
III 1) Docetaxel or paclitaxel 
2) Nivolumab 
 
390 OS 
KEYNOTE 181 
NCT 02564263 
 
Advanced/ metastatic 
≥2nd line 
III 1) Docetaxel or paclitaxel 
2) pembrolizumab 
600 PFS/ OS 
CHECKMATE 577 
NCT 02743494 
 
Adjuvant 
Post pre-op CRT 
Oesophageal and 
OGJ 
 
III 1) Placebo 
2) nivolumab 
760 DFS/ OS 
NCT 02520453 
 
Adjuvant 
Post pre-op CRT 
 
II 1) Placebo 
2) Durvalumab 
84 DFS/ OS 
Colorectal cancer 
 
     
KEYNOTE 177 
NCT 02563002 
 
Advanced/ metastatic 
MSI-H/ dMMR 
1st line 
 
III 1) Standard of care chemotherapy 
(FOLFOX or FOLFIRI ± 
bevacizumab ± cetuximab) 
2) Pembrolizumab 
270 PFS 
36 
Trial protocol /  
NCT ID 
Study setting Phase Treatment Arms Planned 
recruitment 
number of 
patients 
 
Primary outcome 
 
NCI 170057 
NCT 03050814 
 
Advanced/ metastatic 
1st line 
II 1) FOLFOX + bevacizumab 
2) FOLFOX + bevacizumab + Ad-CEA 
+ avelumab 
81 18-month disease 
progression rate  
NCIC CO26 
NCT 02870920 
 
Advanced/ metastatic 
≥ 3rd line 
II 1) Best supportive care 
2) Durvalumab + tremelimumab 
180 OS 
BACCI 
NCT 02873195 
 
Advanced/ metastatic 
≥ 3rd line 
II 1) Capecitabine + bevacizumab + 
placebo 
2) Capecitabine + bevacizumab + 
atezolizumab 
 
135 PFS 
NRG Oncology 
NRG-G1004 
NCT 02997228 
 
Advanced/ metastatic 
MSI-H/dMMR 
1st line 
III 1) FOLFOX + bevacizumab 
2) Atezolizumab 
3) FOLFOX + bevacizumab + 
atezolizumab 
 
439 PFS 
COTEZO 
NCT 02788279 
 
Advanced/ metastatic 
≥ 3rd line 
III 1) Regorafenib 
2) Atezolizumab 
3) Atezolizumab + cobimetinib 
 
360 OS 
ALLIANCE 
A021502 
NCT 02912559 
Adjuvant 
Stage III 
MSI-H/dMMR 
III 1) FOLFOX 
2) FOLFOX + atezolizumab 
720 DFS 
37 
Trial protocol /  
NCT ID 
Study setting Phase Treatment Arms Planned 
recruitment 
number of 
patients 
 
Primary outcome 
  
Pancreatic Cancer 
 
     
GI1616 
NCT 02866383 
Advanced/ metastatic 
≥2nd line 
II 1) Nivolumab + radiotherapy 
2) Nivolumab + ipilimumab + 
radiotherapy 
 
80 Clinical benefit rate 
(CR + PR + SD) 
NCT 02305186 Neoadjuvant II 1) CRT 
2) CRT + Pembrolizumab 
 
56 Tumour infiltrating 
lymphocytes in 
resected pancreatic 
tissue 
 
NCT 02451982 Peri-operative 
Resectable 
 
II 1) GVAX/ cyclophosphamide 
2) GVAX / cyclophosphamide + 
nivolumab 
 
50 Median IL17A 
expression in 
vaccine-induced 
lymphoid aggregates 
in surgically resected 
pancreatic tumour 
 
NCT 03038477 Adjuvant 
Neoadjuvant CRT 
followed by surgery 
 
II 1) Observation 
2) Durvalumab 
114 DFS 
NCIC PA07 Advanced/ metastatic II 1) Gemcitabine + nab-paclitaxel 180 OS 
38 
Trial protocol /  
NCT ID 
Study setting Phase Treatment Arms Planned 
recruitment 
number of 
patients 
 
Primary outcome 
NCT 02879318 1st line 2) Gemcitabine + nab-paclitaxel + 
durvalumab + tremelimumab 
 
 
ORR: objective response rate 
DOR: duration of response 
PFS: progression free survival 
OS: overall survival 
DFS: disease free survival 
SOX: S-1 plus oxaliplatin 
CAPOX: capecitabine plus oxaliplatin 
FOLFOX: 5-FU, leucovorin plus oxaliplatin 
FOLFIRI: 5-FU, leucovorin plus irinotecan 
CRT: chemoradiation 
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OGJ: oesophago-gastric junction 
LAG 3: lymphocyte-activation gene 3 
MMP: matrix metalloproteinase 
MSI-H: microsatellite instability- high 
dMMR: mismatch repair deficient 
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FIGURE LEGEND 
Figure 1 Immune landscape and consensus molecular subgroups in colorectal cancer 
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